Related Experiment Video
Updated: Apr 4, 2026
Author Spotlight: Advanced Ex Vivo Model for Investigating Cancer-Adipose Microenvironment Interaction
Published on: January 26, 2024
Association between adiponectin levels and endometrial carcinoma risk: evidence from a dose-response meta-analysis
Tong Lin1, Xin Zhao1, Wei-min Kong2
1Department of Obstetrics and Gynecology, East Hospital of Beijing University of Traditional Chinese Medicine, Beijing, China.
Objectives:
Epidemiological studies evaluating the association between adiponectin levels and endometrial carcinoma risk have produced inconsistent results. Thus, a meta-analysis was conducted to assess the association between them.
Methods:
Pertinent studies were identified by a search of PubMed and Web of Knowledge through January of 2015. A random-effects model was used to combine the data for analysis. Dose-response relationship was assessed by restricted cubic spline and variance-weighted least squares regression analysis.
Results:
Twelve articles (5 prospective studies and 7 case-control studies) involving 1916 endometrial carcinoma cases were included in this meta-analysis. Pooled results suggested that highest adiponectin levels versus lowest levels were significantly associated with the risk of endometrial carcinoma (summary relative risk (RR)=0.525, 95% CI 0.388 to 0.712, I(2)=64.2%). The association was also found in postmenopausal women (summary RR=0.646, 95% CI 0.433 to 0.964), but not in premenopausal women. A linear dose-response relationship was found, with the risk of endometrial carcinoma decreasing by 3% for every 1 μg/mL increase in adiponectin levels (summary RR=0.97, 95% CI 0.96 to 0.98). No publication bias was found.
Conclusions:
Our analysis suggested that the higher adiponectin levels might have a protective effect against endometrial carcinoma, especially in postmenopausal women.
